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 ABSTRACT 
Purpose 
  
With a dismal 8% median 5-year overall survival (OS), pancreatic ductal           
adenocarcinoma (PDAC) is highly lethal. Only 10-20% of patients, which are eligible            
for surgery, and over 50% of these will die within a year of surgery. ​Building a                
molecular predictor of early death would enable the selection of PDAC patients at             
high risk. 
Materials and Methods 
We developed the Pancreatic Cancer Overall Survival Predictor (PCOSP), a          
prognostic model built from a unique set of 89 PDAC tumors where gene expression              
was profiled using both microarray and sequencing platforms. We used a           
meta-analysis framework based on the binary gene pair method to create gene            
expression barcodes robust to biases arising from heterogeneous profiling platforms          
and batch effects. Leveraging the largest compendium of PDAC transcriptomic          
datasets to date, we show that PCOSP is a robust single-sample predictor of early              
death (≤1 yr) after surgery in a subset of 823 samples with available transcriptomics              
and survival data. 
Results 
The PCOSP model was strongly and significantly prognostic with a meta-estimate of            
the area under the receiver operating curve (AUROC) of 0.70 (P=2.6e-22) and            
hazard ratio (HR) of 1.95(1.6-2.3) (P=1.4e-04) for binary and survival predictions,           
respectively. ​The prognostic value of PCOSP was independent of clinicopathological          
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parameters and molecular subtypes. Over-representation analysis of the PCOSP         
2619 gene-pairs (1070 unique genes) unveiled pathways associated with Hedgehog          
signalling, epithelial mesenchymal transition (EMT) and extracellular matrix (ECM)         
signalling. 
Conclusion 
PCOSP could improve treatment decision by identifying patients who will not benefit            
from standard surgery/chemotherapy and may benefit from a neoadjuvant approach. 
 
INTRODUCTION 
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with 5-year           
overall survival rate less than ​8%​1​. The majority of patients (> 80%) are inoperable              
due to locally advanced or metastatic disease at time of diagnosis. While surgical             
resection is the key to curative treatment, it rarely results in long-term survival​2​.             
Hence, cCompletion of multimodality treatment - surgery combined with adjuvant or           
neoadjuvant chemotherapy- is the standard of care for treatment of PDAC. However,            
even after surgical resection with curative intent, median survival does not exceed 28             
months and half of those who undergo surgery develop recurrent disease, and die             
within a year after surgery ​2–4​. ​Therefore, there is a need for a robust prognostic               
model to identify patients with high risk of early death based on molecular profiles of               
their tumors. Such a prognostic model would assist clinicians in identifying patients            
who might not benefit from surgery and standard adjuvant chemotherapy and may            
benefit from a neoadjuvant approach. Neoadjuvant treatment sequencing is the only           
alternative strategy and may guide selection of patients for surgery and help to             
3 
 
 
identify those patients with progressive disease for whom an operation has little            
oncologic benefit. 
Various clinical factors are prognostic following PDAC surgery such as lymph           
node metastasis status​5​, tumor grade​6​, margins​7​, degree of differentiation​8 ​and          
protein biomarker CA-19-9​9​. However, the prognostic value of these clinical variables           
are insufficient to accurately stratify patients based on risk of disease recurrence​10, 11​.             
With the advent of high-throughput next-generation molecular profiling technologies,         
multiple studies have released transcriptomic profiles of PDAC to the public domain.            
These gene expression profiles have been leveraged to identify molecular subtypes           
of PDACs​12–16​. ​While overlap between these subtypes​15 supports the biological          
relevance of these published classification schemes​15​, they have not been designed           
to optimize prognostic value. 
Previously published prognostic models were developed from small number of          
samples lacking proper validation in multiple datasets​17–21​. Attempts have been made           
recently to build a prognostic gene signature using pooled samples from multiple            
cohorts to identify patients at high risk of short-term survival post surgery​22–24​.            
However, they used samples profiled using either array or sequencing based method            
as the learning cohort, therefore the classifiers may perform better for subjects            
whose samples were profiled using only one of the two platforms​. 
To address these issues, we took advantage of a unique set of 89 PDACs              
profiled using both microarray and sequencing technologies to develop the          
Pancreatic Cancer Overall Survival Predictor (PCOSP) model. Using an independent          
set of PDAC transcriptomic profiles from 823 primary resected patients, we show            
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that PCOSP is a robust single-sample predictor of early death (≤1 yr) after surgery,              
which could be used as as a potential tool to assist clinicians in decision making.               
with a ​meta-estimate of the area under the receiver operating characteristics curve of             
0.70 (p=1.9e-18). We also show that PCOSP is significantly prognostic          
(meta-estimate of hazard ratio of 1.95; p=2.6e-16)​. Furthermore, we show that           
PCOSP performs significantly better than published prognostic models across         
microarray and sequencing datasets (Superiority test, P < 0.01). Our results support            
PCOSP as a potential tool to assist clinicians in decision making. 
  
MATERIALS AND METHODS 
The meta-analysis pipeline used to develop the PCOSP model and evaluate its            
prognostic value is provided in Figure 1. 
  
Datasets 
We surveyed the literature and curated 17 datasets including 1,236 PDAC patients            
from public domain for which transcriptome data of PDAC are available           
(Supplementary Table S1). We further filtered samples based on the availability of            
overall survival (OS) and sample size (>10) after dichotomization into high and low             
survival groups based on an OS cut-off of 1-year (Figure 2). This resulted in a total of                 
four sequencing studies and seven array-based studies providing transcriptomic and          
clinical data for 1,001 PDAC patients. A total of 12,430 protein-coding genes            
commonly assessed across all the cohorts were used for further analysis. The            
different cohorts had similar clinical presentation, and were treated with curative           
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surgery followed by adjuvant chemotherapy, where 2/3rd of the patients completed           
multimodal treatment (i.e., surgery and adjuvant chemotherapy) (Supplementary        
Table S2). 
 
Prognostic model 
To develop a robust predictor for early death, we used the gene expression profiles              
of 89 PDAC patient samples whose tumors have been profiled using both microarray             
and sequencing platforms within the ICGC cohort. Human research ethical approval           
were as mentioned in ​14​. Approximately half of the patients of the training cohort              
which were eligible for surgery relapsed within 1 year, we used this threshold to              
predict PDAC patients with high risk of early death (≤1 yr) post surgery. We excluded               
7 samples from the training cohort as these patients were censored before one year              
of follow-up. 
To make gene expression profiles comparable between the training and          
validation sets, we transformed the original gene expression profiles into binary gene            
pair barcodes. The advantages of considering pairs of genes with a binary value (“1”              
if expression of gene ​i > gene ​j​, “0” otherwise) are; (​i ​) it transforms the feature space                 
in a way that mitigates platform biases and potential batch effects; (​ii​) it makes the               
model robust to any data processing that preserves the gene order​25, 26​. We             
implemented k-Top Scoring disjoint Pairs (k-TSP) classifier predictor​27 ​using the          
Wilcoxon rank sum method as filtering function in the ​SwitchBox package (version            
1.12.0)​28​. 
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The decision rules are based on the relative ordering of gene expression            
values within the same sample, where the ​k top scoring gene pairs are used to build                
the classifier. The samples were resampled 1000 times, where 40 samples from            
each group were selected in each run to build a ​k​-TSP model and the model was                
further tested on the 49 out-of-bag samples. The models were selected if the             
balanced accuracy was above 0.6 else the model was rejected. We then froze the              
parameters of the predictive model and validated it in the remaining compendium of             
independent datasets. The class probability of the sample was calculated as the            
frequency of sample predicted as one class divided by the total number of models. 
  
Random classifiers 
To test whether the prognostic value of the PCOSP model could be achieved by              
random chance alone, we implemented two permutation tests. To test whether the            
gene expression profiles were associated with survival, we shuffled the actual class            
labels while maintaining the expression values. To test whether the gene pairs            
selected in the PCOSP model were robustly associated with survival, we randomly            
assigned genes to the k-TSP model and assessed its prognostic value. Both            
procedures were performed 1000 times. As a pre-validation set we compared the            
balanced accuracy of all the 1000 random models generated using both the            
approaches to PCOSP using the Wilcoxon rank sum test. Further, we trained the             
k-TSP classifier models from both approaches in the same way as we built our              
consensus PCOSP model. We then froze the parameters of the prognostic model            
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and validated it in the compendium of independent datasets, and compared the            
meta-estimates for both the models against the PCOSP model. 
  
Early death prediction 
The meta analysis was performed for the PDAC sequencing cohorts, PDAC           
array-based cohorts and the overall combined cohorts to assess and statistically           
compare the performance of the PCOSP. The patient samples were dichotomized           
into two groups based on the outcome variable (time from surgery to death ≤ 1 year).                
Samples censored before 1 year of follow-up were excluded from the analysis of             
meta-estimate of the area under the receiver operating characteristics curve          
(AUROC). The AUROC plots the sensitivity vs. 1-Specificity and is used as a             
criterion to measure the discriminatory ability of the model ​29​. The AUROC was            
computed using ​pROC package (version 1.10.0), and the p-value was estimated           
using the Mann-Whitney test statistics estimating whether the AUROC curve          
estimate is significantly different from 0.5 (random classifier). The meta-estimate of           
AUROC was estimated using the random effect model​30 implemented in ​survcomp           
package (version 1.26.0)​31, 32​. 
  
Survival prediction 
Prognostic value and statistical significance of survival difference between the          
predicted classes were assessed using the D-Index, which is a robust estimate of              
the traditional Cox’s hazard ratio, more precisely an estimate of the log hazard ratio              
comparing two equal-sized prognostic groups ​33 and is ​a natural measure of separation             
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between two independent survival distributions under the proportional hazards assumption          
33​. In addition, we used the concordance index (C-index) which estimates ​the            
probability that, for a random pair of patients, the PCOSP score for the patient with               
shorter survival is higher than the patient with longer survival ​34​. Both the robust             
hazard ratio (HR) and the C-index were calculated using the ​survcomp ​package. The             
meta estimate of HR and C-index were calculated for the PDAC sequencing cohorts,             
the PDAC array-based cohorts and the combined PDAC sequencing and          
array-based cohorts using the random effect model​30 implemented in ​survcomp          
package. The patients were stratified into low- and high-risk group using median            
PCOSP score as a threshold. Kaplan Meier curves were plotted using survminer            
package (version 0.4.3) ​35​ in R and reported the P values from log-rank test. 
 
Subtyping of PDAC cohorts 
The PDAC cohorts were classified into basal and classical transcriptomic subtype           
using the Moffitt classifier ​13​. 
  
Clinicopathological features based model to predict early death 
The clinical model was built by fitting the logistic regression model using common             
clinicopathological features i.e., age, gender, TNM status and tumor grade available           
from PCSI, ICGC-sequencing, ICGC-array, TCGA and OUH cohorts.  
 
Gene set enrichment analysis 
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To categorize genes in the PCOSP, we performed gene set enrichment analysis            
using RunGSAhyper function implemented in piano package (version 1.16.4)​36​. The          
genes selected in the PCOSP model (n=1,070) were compared against Gene           
Ontology (GO) gene sets, canonical pathways and hallmark gene sets in MSigDb ​37,            
38​, using as background the protein-coding genes commonly assessed across the           
gene expression profiling platforms in our data compendium. Enrichment p-values          
were corrected for multiple testing using the false discovery rate approach (FDR <             
5%)​39​. 
 
Comparison to existing classifiers 
We calculated the Birnbaum signature scores​22 and Chen signature scores​23 using           
the published coefficients of the 25 and 15 classifier genes, respectively, as weight             
parameter in the ​sig.score function implemented in the ​genefu R package (version            
2.10.0)​40​. The Haider signature scores were used as courtesy of the author​24​. The             
C-index and HR were computed for the three classifiers using eight validation            
cohorts excluding the cohorts used for training by PCOSP and other classifiers in             
comparison. Further, we compared the meta-estimates of C-index of each classifier           
with PCOSP at P<0.05 (one-sided t-test) as implemented in ​survcomp​ package. 
  
Research reproducibility 
Our code and documentation are open-source and publicly available through the           
PDACSurv GitHub repository (​github.com/bhklab/PDACsurv ​). A detailed tutorial       
describing how to run our pipeline and reproduce our analysis results is available in              
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the GitHub repository. A virtual machine reproducing the full software environment is            
available on ​Code Ocean​. Our study complies with the guidelines outlined in ​41–43​. All              
the data are available in the form of R package ​MetaGxPancreas​.  
 
RESULTS 
Overall survival predictive model 
To predict the patients with early death (≤ 1 year after surgery), the PCOSP model               
was trained on the 89 ICGC cohort samples profiled using both microarray and             
sequencing transcriptomic profiles (Supplementary Table S1). To develop a predictor          
that can be applied to multiple profiling platforms, we transformed the gene            
expression profiles into binary gene pairs (​x​=1 if expression of gene ​i > gene ​j​, ​x​=0                
otherwise) and used these transcriptomic barcodes in an ensemble of ​1000 ​k-TSP            
predictive models​. The PCOSP score is subsequently calculated using the majority           
voting rule. We tested the prognostic value of PCOSP score in three independent             
sequencing cohorts, including the Pancreatic Cancer Sequencing Initiative (PCSI)​44​,         
TCGA-PAAD​15 and Kirby​45 cohorts, and seven independent array-based cohorts         
composed of ICGC-array (excluding the 89 samples used for training)​46​, UNC​13​,           
OUH​47​, Chen ​23​, Zhang ​48​, Winter​49 and Collisson cohorts​12 ​(Supplementary Table S1).          
We first tested the predictive value of early death by calculating the AUROC for each               
dataset separately (Figure 3A). PCOSP was significant overall (AUROC=0.70;         
P<2.6E-22; Figure 3A), although higher in the datasets generated using sequencing           
platforms compared to microarrays (AUROC 0.72 vs 0.68 for sequencing and array            
datasets, respectively) at ​(P=0.09) suggesting that RNA-sequencing might be a          
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better assay for PCOSP than microarray platforms. PCOSP was significantly          
predictive of early death in all cohorts (AUROC∈[0.67,0.76]; P<0.05) except the           
Winter and OUH cohorts (P>0.48) and was almost significant for the Collisson cohort             
(AUROC=0.69; P=0.051). To determine whether the early death predictive value of           
the PCOSP model can be achieved by random chance alone, we first computed             
meta-estimates of AUROC by randomly shuffling the class labels (early deaths) 1000            
times and applying the same training procedure used for the PCOSP model. We             
observed that the gene expression profiles were significantly associated with survival           
as none of the random models could yield a predictive value greater or equal to               
PCOSP (p<0.001; Supplementary Figure S1A). We further tested whether the gene           
pairs selected in the PCOSP model were robustly associated with early death            
events, by randomly assigning genes to the PCOSP model. Again, we observed that             
the genes selected in PCOSP yielded significantly more predictive information than           
the models comprised of random genes (p<0.001; Supplementary Figure S1B),          
supporting the biological relevance of the PCOSP gene set. 
  
Prognostic relevance of the PCOSP  model 
To assess the prognostic value of the PCOSP model, we calculated the C-indices             
and HR using the overall survival data for all the cohorts. The C-index is significant               
overall (C-index=0.63, P=1.8E-12; Figure 3B). In agreement with the results of early            
death prediction, the PCOSP prognostic value was higher for the sequencing           
datasets when compared to the arrays arrays (C-index=0.65 (P<3.8E-14) vs 0.61           
(P<1.6E-12) for sequencing and array datasets, respectively; Figure 3B). Similar to           
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the C-index, the PCOSP HR was strong and significant overall (HR =1.95,            
P=1.4E-04; Figure 3C), and stronger for the sequencing datasets (HR = 2.24 vs             
1.83; Figure 3C). To assess whether the prognostic value of PCOSP depends on             
PDAC molecular subtypes, we stratified PDAC samples into the basal and classical            
subtypes using Moffitt classifier and calculated meta-estimates of C-index and HR           
(Supplementary Figures S2A and S2B). We found that PCOSP was prognostic in            
validation cohorts independently of molecular subtypes. We further tested whether          
PCOSP prognostic value was complementary to clinicopathological parameters and         
molecular subtypes by fitting both a multivariate Cox proportional hazard model to            
predict survival and a logistic regression model to predict binary outcome (death >1yr             
or not) (Supplementary Table S3).  
 
To further illustrate the prognostic value of PCOSP, we stratified the patients into             
low- and high-risk group and plotted the KM curves for each cohort (Figure 4A-4J).              
The OS were significantly different between the risk groups for all the sequencing             
cohorts and 2 microarray cohorts (P<0.05) and borderline significant for 3 microarray            
cohorts (0.05≤P<0.10; Figure 4A-4J); with 10-month difference in median OS          
between risk groups. 
 
Clinicopathological model to predict overall survival 
The logistic regression model fitted using these clinicopathological features was          
used to predict early death of PDAC patients. The clinicopathological model was not             
significant overall (C-index=0.55; P=0.17; Figure 5A). Contrary to PCOSP, the          
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clinicopathological model was not predictive in the sequencing cohort (C-index=0.53          
and 0.58 with P=0.75 and 0.05 for the sequencing and the array datasets,             
respectively; Figure 5A). Only nodal status, tumor grade and molecular classes were            
significant in the univariate analysis (Supplementary Table S3). We compared the           
prognostic value of the clinicopathological model against PCOSP (Figure 5B,C).          
PCOSP was significantly more prognostic than the clinicopathological model         
(one-sided t-test P < 0.01; Figure 5D). 
  
Comparison with published prognostic models 
We compared the prognostic value of PCOSP to three published PDAC prognostic            
models, referred to as Birnbaum​22​, Chen​23​and Haider​24​. The overall prognostic value           
of the three published models was significant (Figure 6A,C). PCOSP significantly           
outperformed published prognostic models in all cases (P<0.05, Figure 6C,D);          
except for the HR of the Chen classifier where the superiority of the PCOSP              
prognostic value showed a trend to significance (one sided t-test P=0.10) . 
  
Pathway analysis of prognostic genes 
Gene enrichment analysis for PCOSP signature genes (n=1,070) was performed          
using hypergeometric test using the hallmarks gene sets, GO molecular function, GO            
cellular component terms and canonical pathways in MSigDb​37​. The Extracellular          
matrix (ECM), Epithelial Mesenchymal transition (EMT) and hedgehog signalling         
pathway genes were enriched in the PCOSP model at false discovery rate (FDR)             
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<5%. The complete list of GO terms and pathways significantly enriched in the             
PCOSP model are listed in Supplementary Table S4A- 4D. 
 
 
DISCUSSION 
We performed a meta-analysis of the transcriptomic profiles of 1,236 PDAC patients            
and developed PCOSP, a new prognostic model to identify patients with high risk of              
early death after surgery. The model is built from a unique set of 89 patients profiled                
using both array-based and sequencing platforms, and validated on a compendium           
of ten independent datasets, including 823 patients. The prognostic value of the            
PCOSP model was highly significant for both early death (≤1 year) and overall             
survival (P<0.001; Figure 3). 
Contrary to published prognostic signatures fitted on small number of samples           
and lacking validation in large independent datasets​17–21​, PCOSP has been trained           
and validated on a large compendium of datasets. Comparison of PCOSP with            
existing classifiers​22–24 showed that the Birnbaum, Chen and Haider models yielded           
significant but significantly weaker prognostic value than PCOSP (Figure 6C,D).          
Importantly, PCOSP performs significantly better than existing classifiers for both          
microarray and sequencing platforms, likely due to simplifying the continuous          
expression space into binary pair barcodes. This enables PCOSP to be used as a              
single sample predictor robust to profiling platforms, potential batch effects and           
normalization methods compared to other classifiers. 
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Comparison of PCOSP against known prognostic clinicopathological variables        
showed that PCOSP outperformed the clinicopathological model in predicting early          
death (Figure 5). PCOSP prognostic value was significant, even after adjusting for            
molecular subtyping (classical vs basal) and clinicopathological parameters (age,         
sex, TNM status, differentiation grade of tumor and molecular classes)          
(Supplementary Figure S2A,B and Supplementary Table S3). 
The PCOSP model incorporates 2,619 unique gene pairs, totalling 1,070          
unique genes. Functional analysis of 1,070 genes showed enrichment of Hedgehog           
signalling, ECM and EMT pathway. Numerous studies have suggested the          
involvement of EMT in invasion and metastasis of PDAC ​50​. EMT enhances cell            
motility through loss of cell-cell adhesion, escaping from extracellular matrix and           
overcoming the apoptosis process​50​. The ECM and EMT pathways are not only            
associated with the metastatic spread of tumor but also with chemoresistance that            
leads to worse survival​51​. 
PDAC is a heterogeneous and genetically highly complex disease, supporting          
the molecular​13, 14 and morphological​52 characterization of a given tumor as an            
important cornerstone for the development of future therapies. ​We provide the           
largest compendium of 17 PDAC datasets as a gold standard for future PDAC             
analyses. The new meta-analysis framework implemented in PCOSP maximizes         
robustness and performance across the cohorts. In order to implement PCOSP as a             
clinical assay, we tested different feature set sizes for the k-TSP models and             
compared the performance of the reduced models. We achieved accuracy          
comparable to the 1,070 gene-PCOSP model by including only 256 unique genes,            
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supporting the potential of a smaller PCOSP based useful in the clinic            
(Supplementary Figure S3). Endoscopic ultrasound (EUS) biopsies could be utilized          
prior to curative surgery to estimate the prognosis of PDAC patients using PCOSP.             
This may assist clinicians in the selection of patients for surgery and help to identify               
those patients with high risk progressive disease for whom an operation has little             
oncologic benefit. 
The current study has potential limitations. First, there are inherent tumor           
sample collection biases as the different datasets were collected and sampled at            
different centers. The levels of tumor cellularity varied highly across cohorts as PCSI             
and Collisson datasets were generated using laser microdissection prior to          
sequencing, Kirby and Chen datasets were macrodissected, while TCGA, ICGC,          
OUH, Zhang and Winter datasets used bulk tumors for profiling. Second, the            
transcriptomic profiles in our data compendium were generated using different gene           
expression profiling technologies for sequencing (Illumina HiSeq 2000/2500) and         
microarray platforms (Agilent, Affymetrix, and Illumina). Third, all samples were          
normalized using the published processing methods, which depend on the profiling           
platforms (Supplementary Table S2). Despite these limitations, PCOSP yielded         
robust prognostic value across the heterogeneous datasets, indicating that the gene           
expression barcode transformation is robust to the inevitable biases present in large            
meta-analyse ​s. However, exploring other factors like germline variants, epigenetics,         
copy number alterations, non-coding RNAs, protein abundance as well as          
epidemiological and environmental factors will be necessary to further improve the           
prediction accuracy of predictive models. 
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The lack of available clinical and treatment information across the cohorts is            
also a limiting factor in our meta-analysis. However, comparison of cohort specific            
clinical information for the cohort were not significantly different across the cohorts            
(Supplementary table S2). During the time period of sample collection, standard of            
care treatment for PDAC was curative-intent surgery followed by adjuvant          
chemotherapy with gemcitabine or 5-FU. New approaches using doublet and triplet           
chemotherapy regimens are now standard of care in the palliative setting and            
randomised trials using these agents in the adjuvant setting will be reported shortly.             
Neoadjuvant therapy is also being evaluated in many centres. Thus, heterogeneity in            
treatment is expected within and between different cohorts, we will need to test our              
PCOSP model using new clinical datasets, or preferably within the context of            
randomized trials. 
 
CONCLUSION 
We leveraged the largest compendium of PDAC transcriptomes to develop PCOSP,           
a prognostic model identifying PDAC patients at high risk of early death            
independently of, and superior to, clinicopathological features and molecular         
subtypes. PCOSP may be useful in the clinical setting as a single sample classifier              
to identify patients who could be at higher risk of early death following surgery and               
adjuvant chemotherapy, potentially facilitating treatment decisions, including the use         
of neoadjuvant chemotherapy as an alternative treatment strategy for these patients. 
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AUROC: Area under the receiver operating curve, GO: Gene annotation, OS: Overall            
survival, PCOSP: Pancreatic cancer overall survival predictor, PDAC: Pancreatic         
ductal adenocarcinoma, TSP: Top scoring pairs. 
 
 
Declarations: 
Open Access 
This article is distributed under the terms of the Creative Commons Attribution 4.0             
International License (​http://creativecommons.org/licenses/by/4.0/​), which permits     
unrestricted use, distribution, and reproduction in any medium, provided you give           
appropriate credit to the original author(s) and the source, provide a link to the              
Creative Commons license, and indicate if changes were made. 
 
Competing interests 
The authors declare that they have no competing interests. 
 
Acknowledgements 
This study was conducted with the support of the Ontario Institute for Cancer             
Research (OICR, PanCuRx Translational Research Initiative) through funding        
19 
 
 
provided by the Government of Ontario (Ministry of Research, Innovation, and           
Science), and a charitable donation from the Canadian Friends of the Hebrew            
University (Alex U. Soyka). V.S was supported by grants from The Radium Hospital             
Foundation, Oslo University Hospital, and the PanCuRx Translational Research         
Initiative at the OICR. B.H.K was supported by the Gattuso Slaight Personalized            
Cancer Medicine Fund at Princess Margaret Cancer Centre, the Canadian Institutes           
of Health Research, the Natural Sciences and Engineering Research Council of           
Canada, and the Ministry of Economic Development and Innovation/Ministry of          
Research & Innovation of Ontario (Canada). We thank Dr. Syed Haider for            
courteously providing the prediction scores from his classifier for comparison with           
PCOSP.​ ​We thank all the patients who participated in the study. 
  
20 
 
 
REFERENCES 
1​. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2017. CA Cancer J Clin 67:7–30,               
2017 
2​. Winter JM, Brennan MF, Tang LH, et al: Survival after resection of pancreatic              
adenocarcinoma: results from a single institution over three decades. Ann Surg           
Oncol 19:169–175, 2012 
3​. Labori KJ, Katz MH, Tzeng CW, et al: Impact of early disease progression and               
surgical complications on adjuvant chemotherapy completion rates and survival in          
patients undergoing the surgery first approach for resectable pancreatic ductal          
adenocarcinoma – A population-based cohort study. Acta Oncol 55:265–277, 2016 
4​. Neoptolemos JP, Palmer DH, Ghaneh P, et al: Comparison of adjuvant            
gemcitabine and capecitabine with gemcitabine monotherapy in patients with         
resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised,        
phase 3 trial. Lancet 389:1011–1024, 2017 
5​. Slidell MB, Chang DC, Cameron JL, et al: Impact of total lymph node count and                
lymph node ratio on staging and survival after pancreatectomy for pancreatic           
adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 15:165–174,         
2008 
6​. Lüttges J, Schemm S, Vogel I, et al: The grade of pancreatic ductal carcinoma is                
an independent prognostic factor and is superior to the immunohistochemical          
21 
 
 
assessment of proliferation. J Pathol 191:154–161, 2000 
7​. Richter A, Niedergethmann M, Sturm JW, et al: Long-term results of partial             
pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head:        
25-year experience. World J Surg 27:324–329, 2003 
8​. Imaoka H, Shimizu Y, Mizuno N, et al: Clinical characteristics of adenosquamous             
carcinoma of the pancreas: a matched case-control study. Pancreas 43:287–290,          
2014 
9​. Tas F, Karabulut S, Ciftci R, et al: Serum levels of LDH, CEA, and CA19-9 have                 
prognostic roles on survival in patients with metastatic pancreatic cancer receiving           
gemcitabine-based chemotherapy. Cancer Chemother Pharmacol 73:1163–1171,      
2014 
10 ​. Le N, Sund M, Vinci A, et al: Prognostic and predictive markers in pancreatic               
adenocarcinoma. Dig Liver Dis 48:223–230, 2016 
11 ​. Martinez-Useros J, Garcia-Foncillas J: Can Molecular Biomarkers Change the          
Paradigm of Pancreatic Cancer Prognosis? Biomed Res Int 2016:4873089, 2016 
12 ​. Collisson EA, Sadanandam A, Olson P, et al: Subtypes of pancreatic ductal             
adenocarcinoma and their differing responses to therapy. Nat Med 17:500–503,          
2011 
13 ​. Moffitt RA, Marayati R, Flate EL, et al: Virtual microdissection identifies distinct             
tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat         
22 
 
 
Genet 47:1168–1178, 2015 
14 ​. Bailey P, Chang DK, Nones K, et al: Genomic analyses identify molecular             
subtypes of pancreatic cancer. Nature 531:47–52, 2016 
15 ​. Raphael BJ, Hruban RH, Aguirre AJ, et al: Integrated Genomic Characterization            
of Pancreatic Ductal Adenocarcinoma. Cancer Cell 32:185–203.e13, 2017 
16 ​. Sandhu V, Wedge DC, Bowitz Lothe IM, et al: The Genomic Landscape of              
Pancreatic and Periampullary Adenocarcinoma. Cancer Res 76:5092–5102, 2016 
17 ​. Van den Broeck A, Vankelecom H, Van Delm W, et al: Human pancreatic cancer               
contains a side population expressing cancer stem cell-associated and prognostic          
genes. PLoS One 8:e73968, 2013 
18 ​. Donahue TR, Tran LM, Hill R, et al: Integrative survival-based molecular profiling             
of human pancreatic cancer. Clin Cancer Res 18:1352–1363, 2012 
19 ​. Sergeant G, van Eijsden R, Roskams T, et al: Pancreatic cancer circulating             
tumour cells express a cell motility gene signature that predicts survival after            
surgery. BMC Cancer 12:527, 2012 
20 ​. Newhook TE, Blais EM, Lindberg JM, et al: A thirteen-gene expression signature             
predicts survival of patients with pancreatic cancer and identifies new genes of            
interest. PLoS One 9:e105631, 2014 
21 ​. Stratford JK, Bentrem DJ, Anderson JM, et al: A six-gene signature predicts             
survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med          
23 
 
 
7:e1000307, 2010 
22 ​. Birnbaum DJ, Finetti P, Lopresti A, et al: A 25-gene classifier predicts overall              
survival in resectable pancreatic cancer. BMC Med 15:170, 2017 
23 ​. Chen D-T, Davis-Yadley AH, Huang P-Y, et al: Prognostic Fifteen-Gene           
Signature for Early Stage Pancreatic Ductal Adenocarcinoma. PLoS One         
10:e0133562, 2015 
24 ​. Haider S, Wang J, Nagano A, et al: A multi-gene signature predicts outcome in               
patients with pancreatic ductal adenocarcinoma. Genome Med 6:105, 2014 
25 ​. Patil P, Bachant-Winner P-O, Haibe-Kains B, et al: Test set bias affects             
reproducibility of gene signatures. Bioinformatics 31:2318–2323, 2015 
26 ​. Eddy JA, Sung J, Geman D, et al: Relative expression analysis for molecular              
cancer diagnosis and prognosis. Technol Cancer Res Treat 9:149–159, 2010 
27 ​. Tan AC, Naiman DQ, Xu L, et al: Simple decision rules for classifying human               
cancers from gene expression profiles. Bioinformatics 21:3896–3904, 2005 
28 ​. Afsari B, Fertig EJ, Geman D, et al: switchBox: an R package for k-Top Scoring                
Pairs classifier development. Bioinformatics 31:273–274, 2015 
29 ​. Harrell FE Jr, Califf RM, Pryor DB, et al: Evaluating the yield of medical tests.                
JAMA 247:2543–2546, 1982 
30 ​. Cochran WG: The Combination of Estimates from Different Experiments.          
24 
 
 
Biometrics 10:101–129, 1954 
31 ​. Schröder MS, Culhane AC, Quackenbush J, et al: survcomp: an R/Bioconductor            
package for performance assessment and comparison of survival models.         
Bioinformatics 27:3206–3208, 2011 
32 ​. Haibe-Kains B, Desmedt C, Sotiriou C, et al: A comparative study of survival              
models for breast cancer prognostication based on microarray data: does a single            
gene beat them all? Bioinformatics 24:2200–2208, 2008 
33 ​. Royston P, Sauerbrei W: A new measure of prognostic separation in survival             
data. Stat Med 23:723–748, 2004 
34 ​. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: issues in             
developing models, evaluating assumptions and adequacy, and measuring and         
reducing errors. Stat Med 15:361–387, 1996 
35 ​. Kassambara A, Kosinski M, Biecek P: survminer: Drawing Survival Curves           
using’ggplot2’. R package version 0 3 1, 2017 
36 ​. Väremo L, Nielsen J, Nookaew I: Enriching the gene set analysis of             
genome-wide data by incorporating directionality of gene expression and combining          
statistical hypotheses and methods. Nucleic Acids Res 41:4378–4391, 2013 
37 ​. Liberzon A, Subramanian A, Pinchback R, et al: Molecular signatures database            
(MSigDB) 3.0. Bioinformatics 27:1739–1740, 2011 
38 ​. Liberzon A, Birger C, Thorvaldsdóttir H, et al: The Molecular Signatures            
25 
 
 
Database (MSigDB) hallmark gene set collection. Cell Syst 1:417–425, 2015 
39 ​. Benjamini Y, Hochberg Y: Controlling the False Discovery Rate: A Practical and             
Powerful Approach to Multiple Testing. J R Stat Soc Series B Stat Methodol             
57:289–300, 1995 
40 ​. Gendoo DMA, Ratanasirigulchai N, Schröder MS, et al: Genefu: an           
R/Bioconductor package for computation of gene expression-based signatures in         
breast cancer. Bioinformatics 32:1097–1099, 2016 
41 ​. Sandve GK, Nekrutenko A, Taylor J, et al: Ten simple rules for reproducible              
computational research. PLoS Comput Biol 9:e1003285, 2013 
42 ​. Gentleman R: Reproducible research: a bioinformatics case study. Stat Appl           
Genet Mol Biol 4:Article2, 2005 
43 ​. Stroup DF, Berlin JA, Morton SC, et al: Meta-analysis of Observational Studies in              
Epidemiology: A Proposal for Reporting. JAMA 283:2008–2012, 2000 
44 ​. Notta F, Chan-Seng-Yue M, Lemire M, et al: A renewed model of pancreatic              
cancer evolution based on genomic rearrangement patterns. Nature 538:378–382,         
2016 
45 ​. Kirby MK, Ramaker RC, Gertz J, et al: RNA sequencing of pancreatic             
adenocarcinoma tumors yields novel expression patterns associated with long-term         
survival and reveals a role for ANGPTL4. Mol Oncol 10:1169–1182, 2016 
46 ​. Nones K, Waddell N, Song S, et al: Genome-wide DNA methylation patterns in              
26 
 
 
pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO,        
ITGA2 and MET signaling. Int J Cancer 135:1110–1118, 2014 
47 ​. Sandhu V, Bowitz Lothe IM, Labori KJ, et al: Molecular signatures of mRNAs and               
miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of          
periampullary adenocarcinomas. Mol Oncol 9:758–771, 2015 
48 ​. Zhang G, Schetter A, He P, et al: DPEP1 inhibits tumor cell invasiveness,              
enhances chemosensitivity and predicts clinical outcome in pancreatic ductal         
adenocarcinoma. PLoS One 7:e31507, 2012 
49 ​. Winter C, Kristiansen G, Kersting S, et al: Google goes cancer: improving             
outcome prediction for cancer patients by network-based ranking of marker genes.           
PLoS Comput Biol 8:e1002511, 2012 
50 ​. Zheng X, Carstens JL, Kim J, et al: Epithelial-to-mesenchymal transition is            
dispensable for metastasis but induces chemoresistance in pancreatic cancer.         
Nature 527:525–530, 2015 
51 ​. Gaianigo N, Melisi D, Carbone C: EMT and Treatment Resistance in Pancreatic             
Cancer [Internet]. Cancers 9, 2017Available from:      
http://dx.doi.org/10.3390/cancers9090122 
52 ​. FUKUSHIMA, N: Ductal adenocarcinoma variants and mixed neoplasm of the           
pancreas. WHO Classification of Tumours of the Digestive System 292–295, 2010 
  
27 
 
 
  
28 
 
 
FIGURES 
Figure 1​. Pipeline showing the approach used for building the Pancreatic Cancer            
Overall Survival Predictor (PCOSP). 
Figure 2: ​Flowchart showing the inclusion criteria for the pancreatic adenocarcinoma           
samples. 
Figure 3. Predictive value of PCOSP for early death and overall survival. (A)             
Area under the ROC curves for all the cohorts and the meta estimates for              
sequencing cohorts, array-based cohorts and for both the platforms combined.          
Forestplot reporting (​B​) the concordance indices (C-index) and (​C​) the hazard ratio            
(HR) for all the cohorts and the meta estimates for sequencing cohorts (orange),             
array-based cohorts (blue) and for both the platforms combined (grey). 
Figure 4. Kaplan Meier survival curves ​for ​(A) ​PCSI (B) TCGA ​(C ) ​Kirby ​(D)               
ICGC-array ​(E) UNC (F) ​Chen ​(G) OUH ​(H) Zhang (I) ​Winter and ​(J) ​Collisson. The               
overall survival difference between high and low risk group is 13 and 23 months              
respectively. 
Figure 5. Comparison of the prognostic value of the clinicopathological model           
and PCOSP. (A) ​Barplot reporting the AUROCs for the clinical model and the             
PCOSP model. ​(​Forestplot reporting the the (​B​) concordance index (C-index) and           
(​C​) Hazard ratio (HR) of validation cohorts computed using PCOSP, and           
clinicopathological model. 
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Figure 6. ​Comparison of existing classifiers with PCOSP. ​The forestplot reports           
the meta-estimate of (​A​) concordance indices (C-index) and (​B ​) hazard ratio (HR) for             
PCOSP and existing classifiers. 
  
SUPPLEMENTARY FIGURES 
  
Supplementary Figure S1: Density plot showing the distribution of balanced          
accuracy for random models. ​Distribution of meta-estimates of 1000 models          
generated using (​A​) random reshuffling of labels and (​B​) random assignment of            
genes to TSP models. The meta-estimates were independently calculated for all the            
cohorts combined, sequencing cohorts and array-based cohort. The pink, green,          
blue dashed lines represent meta-estimate of AUROC from PCOSP model for           
overall, sequencing and array-based cohorts respectively. 
  
Supplementary Figure S2: ​Forestplot of (​A ​) concordance index (C-index) and (​B​)           
hazard ratio (HR) for all the cohorts divided based on the molecular subtypes. The              
grey, green and pink color in the forestplot depicts meta-estimate of C-index for             
overall cohort, the basal subtype and the classical subtype of the cohorts,            
respectively. 
  
Supplementary Figure S3: The scatterplot shows the meta-estimate of AUROC           
(orange) and total number of unique genes (blue) in the PCOSP model at different              
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balanced accuracy thresholds. The threshold used in the PCOSP is marked as            
dashed line at 0.6. 
  
SUPPLEMENTARY TABLES 
  
Supplementary Table S1: ​The table shows the datasets used in the project for             
meta-analysis. 
  
Supplementary Table S2: ​The table shows the clinicopathological information of the           
validation cohorts used in the analysis. 
  
Supplementary Table S3: Univariate and multivariate regression analysis.from (​A​)         
logistic regression model to predict early death (death >1 yr or not), and (​B ​). the Cox                
regression model using clinicopathological features, molecular subtypes and PCOSP         
model probabilities for validation cohorts. 
  
Supplementary table S4: The table shows the pathways overrepresented in the           
PCOSP model genes using (​A​) hallmark gene sets, (​B ​) canonical pathways, (​C​)            
GO-molecular function term (and (​D​) GO cellular component terms from MSigDB. 
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